 "US FDA approves Natco Pharma's anti-cancer drug azacitidine")
Natco Pharma Limited has received final approval from the US Food and Drug Administration (FDA) for azacitidine injection used in the treatment of cancer. “Natco Pharma Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US FDA for azacitidine for injection, 100 mg per vial, single-dose vial - a generic version of Vidaza by Celgene Corporation,” said the company in a press release.
Natco and its marketing partner Breckenridge Pharmaceutical Inc (BPI) plan to launch this product in the US market in the near future.
Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $ 188 million for the twelve-month period ending April, 2017, based on industry sales data.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%